1. Inicio
  2. Publicaciones
  3. Haploidentical transplantation is associated with better overall survival when compared to single cord blood transplantation: an EBMT-Eurocord study of acute leukemia patients conditioned with thiotepa, busulfan, and fludarabine

Haploidentical transplantation is associated with better overall survival when compared to single cord blood transplantation: an EBMT-Eurocord study of acute leukemia patients conditioned with thiotepa, busulfan, and fludarabine

Fecha de publicación:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Giannotti, F
  • Labopin, M
  • Shouval, R
  • Arcese, W
  • Angelucci, E
  • Sierra, J
  • Santasusana, JMR
  • Santarone, S
  • Benedetto, B
  • Rambaldi, A
  • Saccardi, R
  • Blaise, D
  • Carella, MA
  • Rocha, V
  • Baron, F
  • Mohty, M
  • Ruggeri, A
  • Nagler, A

Grupos

Abstract

Background: Thiotepa-busulfan-fludarabine (TBF) is a widely used conditioning regimen in single umbilical cord blood transplantation (SUCBT). More recently, it was introduced in the setting of non-T cell depleted haploidentical stem cell transplantation (NTD-Haplo). Whether TBF based conditioning provides additional benefit in transplantation from a particular alternative donor type remains to be established. Methods: This was a retrospective study based on an international European registry. We compared outcomes of de-novo acute myeloid leukemia patients in complete remission receiving NTD-Haplo (n = 186) vs. SUCBT (n = 147) following myeloablative conditioning (MAC) with TBF. Median follow-up was 23 months. Treatment groups resembled in baseline characteristics. Results: SUCBT was associated with delayed engraftment and higher graft failure. In multivariate analysis no statistically significant differences were observed between the two groups in terms of acute or chronic graft-versus-host disease (GvHD) (HR = 1.03, p = 0.92 or HR = 1.86, p = 0.21) and relapse incidence (HR = 0.8, p = 0.65). Non-relapse mortality (NRM) was significantly higher in SUCBT as compared to NTD-Haplo (HR = 2.63, p = 0.001); moreover, SUCBT did worse in terms of overall survival (HR = 2.18, p = 0.002), leukemia-free survival (HR = 1.94, p = 0.007), and GvHD relapse-free survival (HR = 2.38, p = 0.0002). Conclusions: Our results suggest that TBF-MAC might allow for a potent graft-versus-leukemia, regardless of the alternative donor type. Furthermore, in patients receiving TBF-MAC, survival with NTD-Haplo may be better compared to SUCBT due to decreased NRM.

Datos de la publicación

ISSN/ISSNe:
1756-8722, 1756-8722

JOURNAL OF HEMATOLOGY & ONCOLOGY  BMC

Tipo:
Article
Páginas:
110-110
Factor de Impacto:
2,960 SCImago ℠
Cuartil:
Q1 SCImago ℠

Citas Recibidas en Web of Science: 34

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • Acute myeloid leukemia; Stem cell transplantation; Conditioning regimens; Thiotepa-busulfan-fludarabine; Haploidentical stem cell transplantation; Umbilical cord blood transplantation

Campos de estudio

Proyectos asociados

MECANISMOS DE ENFERMEDAD EN LA MIOCARDIOPATIA ARRITMOGENICA, MEJORAS EN SU DIAGNOSTICO Y BUSQUEDA DE DIANAS TERAPEUTICAS.

Investigador Principal: ESTHER ZORIO GRIMA

PI14/01477 . INSTITUTO DE SALUD CARLOS III . 2015

INCORPORACIÓN GRUPOS CIBER. DR. DOLZ

Investigador Principal: LUIS VICENTE MARTÍNEZ DOLZ

CB16/11/00261 . INSTITUTO DE SALUD CARLOS III . 2017

ESTUDIO MULTICÉNTRICO, ALEATORIZADO, DOBLE CIEGO, BASADO EN EVENTOS, QUE COMPARA LA EFICACIA Y SEGURIDAD DE RIVAROXABAN CON PLACEBO EN LA REDUCCIÓN DEL RIESGO DE MUERTE, INFARTO DE MIOCARDIO O ICTUS, EN PACIENTES CON INSUFICIENCIA CARDIACA Y ENFERMEDAD ARTERIAL CORONARIA SIGNIFICATIVA TRAS UN EPISODIO DE INSUFICIENCIA CARDIACA DESCOMPENSADA.

Investigador Principal: LUIS ALMENAR BONET

RIVAROXHFA3001/BAY59-7939/16302 . 2013

EVALUACIÓN, EN PACIENTES CON PROCESOS MÉDICOS, DE RIVAROXABAN FRENTE A PLACEBO EN LA REDUCCIÓN DEL RIESGO DE TROMBOEMBOLISMO VENOSO DESPUÉS DEL ALTA HOSPITALARIA. (MARINER).

Investigador Principal: JOSÉ ANTONIO TODOLÍ PARRA

RIVAROXDVT3002/BAY59-7939/17261

Cita

Compartir